Quality of life measurement in cancer patients before and after chemotherapy with EORTC QLQ-C30 in RSUP Dr. Sardjito Yogyakarta
The research about cancer patients’ quality of life on before and after therapy of high emetogenic cytotostatic in RSUP Dr Sardjito Yogyakarta by EORTC QLQ-C30 has been done.
This research used cohort design with cancer patients who just the first time received cisplatin ≥ 50 mg/m2 and or its combination, and also got ondansetron-dexamethasone as anti-emetics. While the patients were given EORTC QLQ-C30 questionnaire before got cisplatin (before chemotherapy) and 5 days after got cisplatin (after chemotherapy). The difference of the quality of the life will be analysed with paired t-test with 95 % level of significancy. The correlation between the domains before and after chemotherapy was analysed by Pearson correlation test with the 95 % level of significancy.
We got 38 patients during 2 months with the cancer diagnoses of cervix, nasopharyng, ovarium and lung. Generally, the quality of life was nonsignificantly decreasing, whereas not all the domains were decreasing. The physical, emotions, cognitive and social domains were non-significantly increasing. The decline in the quality of life was more influenced by the role domain of the patients, pain, the decline in appetite and the financial difficulty. The correlation of fatigue, constipation and the financial difficulty were strong between the domain in before and the chemotherapy after was received in the symptom (r ≈ 0.50).
Key words : quality of life, cancer, EORTC QLQ-C30.
Awad M.A., Denic S. and El Taji H., 2008, Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires for Arabic-speaking Populations, Ann. N.Y.Acad.Sci, 1138, 146–154.
Balatori, E. and Roila F., 2003, Impact of Nausea and Vomitting on Quality of Life in Cancer Patients during Chemotherapy, Health Qual. of Life Outcome, 1,46, 1-11.
Bottomley A., 2002, The Cancer Patients and Quality of Life, Oncologist,7, 120-125.
Fredheim O.M.S., Borchgrevink P.C., Saltnes T. and Kaasa S., 2007, Validation and Comparison of the Health-Related Quality-of-Life Instruments EORTC QLQ-C30 and SF-36 in Assessment of Patients with Chronic Nonmalignant Cancer, J Pain Symptom Manage, 34, 657-665.
Hesketh , P.J., 1999, Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice, Oncologist; 4, 191-196.
Kleijn W.Chr., Ogoshi K., Yamaoka K., Shigehisa T., Takeda Y., Creutzberg C.L., Nortier J.W.R. and Kaptein A.A., 2006, Conceptual equivalence and health-related quality of life: an exploratory study in Japanese and Dutch cancer patients. Qual. Life Res., 15, 1091– 1101.
Koda-Kimble, M.A, Young L.Y., Kradjan, W.A., and Guglielmo, B.J., 2002, Applied Theurapeutics, Lippincot Williams &Wilkins, New York, p 84.1-84-85.
Luo N., Fones C.S.L., Lim S.E., Xie F., Thumbo J. and Li S.C., 2005, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQC30): Validation of English version in Singapore, Qual. Life Res., 14, 1181–1186.
Soetiarto, F., 2001, Registrasi Kanker Populasi di Kodya Ujing Pandang, Yogyakarta dan Semarang tahun 1996, Center for Research and Development of Disease Control, NIHRD, Badan Penelitian dan Pengembangan Kesehatan, Jakarta, hal 1.
Tierney, L.M., McPhee, S.J. and Papadakis, M.A., 2006, Current Medical Diagnosis and Treatment, The McGraw -Hil, New York, p 97-98.
Wan C., Meng Q., Yang Z., Tu X., Feng C., Tang X. and Zhang C., 2008, Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer, Ann. Oncol.,19,2053–2060.
Zhao H. and Kanda K., 2000, Translation and validation of the Standard Chinese version of the EORTC QLQ-C30. Qual. Life Res., 9,129-137.
- There are currently no refbacks.
Copyright (c) 2017 INDONESIAN JOURNAL OF PHARMACY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Indonesian J Pharm indexed by:
View My Stats